EODData

MEMBERSHIP REGISTER LOG IN

FRA, 0PT: Prothena Corporation plc

24 Mar 2026
LAST:

7.350

CHANGE:
 0.00		OPEN:
7.450		HIGH:
7.450		ASK:
0.000		VOLUME:
600
CHG(%):
0.00		PREV:
7.350		LOW:
7.350		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Mar 267.4507.4507.3507.350600
23 Mar 267.3507.3507.3507.350600
20 Mar 267.2507.3507.2507.350600
19 Mar 267.3507.3507.2007.2000
18 Mar 267.7507.7507.3007.3000
17 Mar 267.8507.8507.6507.6500
16 Mar 268.0008.0007.7507.7500
13 Mar 267.9507.9507.8507.8500
12 Mar 268.1008.1007.9007.900600
11 Mar 268.2508.2508.1008.100600

PROFILE

Name:Prothena Corporation plc
About:Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Sector:Healthcare
Industry:Biotechnology
Address:77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60
Website:https://www.prothena.com
ISIN:IE00B91XRN20

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-3.48 
Forward P/E:-3.48 
PEG Ratio:0.09 
Price to Sales:36.84 
Price to Book:1.70 
Operating Margin:-16.46 
Return on Assets:-0.29 
Return on Equity:-0.68 
Revenue:10.01M 
Shares:53.83M 
Market Cap:395.65M 

TECHNICAL INDICATORS

MA5:7.310.5%
MA10:7.583.1%
MA20:7.714.9%
MA50:7.643.9%
MA100:8.089.9%
MA200:7.271.1%
STO9:16.67 
STO14:12.50 
RSI14:25.00 
WPR14:-86.36 
MTM14:-0.60
ROC14:-0.08 
ATR:0.20 
Week High:7.856.8%
Week Low:7.202.1%
Month High:8.4014.3%
Month Low:7.151.1%
Year High:12.4168.8%
Year Low:3.8491.4%
Volatility:5.18